Zusduri, a product of Urogen Pharma, is gaining market traction against competitors like MSD's Keytruda and Ferring's Adstiladrin.
2 reports, 2 independent
Updated Aug 5
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Zusduri, a product of Urogen Pharma, is gaining market traction against competitors like MSD's Keytruda and Ferring's Adstiladrin.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.ZUSDURI drives revenue growth, while JELMYTO revenue remains stable.1 source
Zusduri's success is noted against Keytruda and Adstiladrin, with J&J's Balversa as a counter-force.1 source
Keep exploring
The entities involved
-
MSD
company in Rome, Italy
-
Ferring Pharmaceuticals
company
Nothing else this week.
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- Clinical Trials ArenaUroGen’s Zusduri benefit maintained in NMIBC Phase III study UroGen Pharma’s Zusduri (mitomycin) has continued to show benefit after two years in patients with non-muscular invasive bladder cancer (N